Abbott Compound Library Near 1 Mil., Company Tells Analysts At R&D Day
Executive Summary
Abbott's compound library is nearing 1 mil. molecules, the company told securities analysts during its June 21 R&D day in New York.
You may also be interested in...
Abbott Will Study Prostate Cancer Drug Atrasentan For Early-Stage/Prevention
Abbott plans to file an NDA for its prostate cancer therapy atrasentan in late 2003, the company told securities analysts at its June 21 R&D Day in New York City.
Abbott Will Study Prostate Cancer Drug Atrasentan For Early-Stage/Prevention
Abbott plans to file an NDA for its prostate cancer therapy atrasentan in late 2003, the company told securities analysts at its June 21 R&D Day in New York City.
Abbott Expects RA Agent D2E7 To Capture 25% Of Market, Touts Production
Abbott predicts it has existing production capacity for its rheumatoid arthritis treatment D2E7 (adalimumab) to serve the market up to five years, even at ambitious growth projections.